OKYO Pharma
validation efficacy in dry eye mouse model | OKYO Pharma
Company
Deck Type
Sector
Industry
Deck date
June 2023
Slide
13 of 25
Related slides by other companies
Fusion Pharmaceuticals
IPO
June 2020
enhanced efficacy in a mouse tumor model | Fusion Pharmaceuticals
Recursion Pharmaceuticals
Investor Day
January 2023
clinical efficacy found in in mice models led to significant progression free survival further confidence preclinical studies confirming insight | Recursion Pharmaceuticals
Matinas BioPharma
Investor Presentation
January 2024
enact phase clinical validation of safety and efficacy | Matinas BioPharma
Bausch+Lomb
Results
May 2023
building a global dynamic dry eye disease platform dry eye total revenue for | Bausch+Lomb
Other recent decks by OKYO Pharma
See all presentations (2 decks)
Shareholder Engagement
March 2020
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights